Take Action
The policies that govern Lipedema care vary by country. Knowing where your country stands is the first step to changing it.
Take Action
The policies that govern Lipedema care vary by country. Knowing where your country stands is the first step to changing it.
Lipedema recognition, funding, and clinical guidelines differ dramatically from one country to the next. The UK has NICE guidance (NG203, 2022). The US gained ICD-11 recognition. Ireland and Australia lag behind in formal policy. In every country, the gaps between what the guidelines say and what patients can actually access remain significant. Understanding the landscape in your country is the first step to effective advocacy.
Policy determines what care is available to you. It determines whether your GP has been trained to recognise Lipedema, whether your health service will fund your treatment, and whether your insurer must cover it.
In most countries, the policy landscape for Lipedema is still being built. There has been real progress, particularly in the UK and the US, but that progress has not translated evenly into what patients can actually access. The gap between what guidelines say and what happens in a consulting room remains wide.
Lipedema has been in the medical literature since 1940. It affects an estimated 6 to 11 percent of women. And in most countries, the majority of affected women have never been correctly diagnosed.
That is not primarily a question of individual doctors failing. It is a systemic failure: of medical education, of guideline implementation, of research funding, and of political will. The research community and patient advocacy organisations have produced increasingly strong evidence and increasingly clear guidance. The policy infrastructure to act on that guidance is still catching up.
When a country has a dedicated clinical guideline, GPs learn about the condition. When treatment is funded, women can access it. When a diagnosis has an ICD code, insurers must engage with it. Policy is not abstract. It is the mechanism by which evidence becomes care.
The 2024 Lipedema World Alliance Delphi Consensus, representing specialists from multiple countries, sets out what a comprehensive policy framework for Lipedema should include:
No country currently meets all of these criteria. The tracker above shows where each country stands against the key benchmarks.
If you are in Ireland, the UK, the US, or Australia, the accordion above gives you a snapshot of where your country stands. Check which gaps are most significant in your jurisdiction, then use the template letters to contact the people who have the power to close them.
If your country is not listed, contact us. We are building out the tracker and want to include more jurisdictions.
Every improvement in the policy landscape for Lipedema has been driven, at least in part, by patients. The NICE guideline in the UK came after years of advocacy by patient organisations and individual women writing to their MPs. The ICD-11 inclusion came after sustained pressure from the research and patient community.
Individual advocacy is not the most comfortable position for most people. You are unwell. You are tired. You have been fighting for your own diagnosis. Being asked to also fight for systemic change is a significant ask.
But collective, coordinated advocacy works. The campaigns and tools on this site are designed to make it as low-effort and high-impact as possible.
Evidence rating: Strong for the factual policy landscape described on this page. The guidelines, recognition decisions, and funding gaps referenced here are documented in official guideline publications, WHO documents, and peer-reviewed literature.
The 2021 US Standard of Care, the NICE NG203 guideline (2022), and the 2024 Lipedema World Alliance Delphi Consensus provide the clearest international benchmarks for what good Lipedema policy should include. Progress in implementation consistently lags behind the guidelines.
Policy changes when people push for it. The tracker below shows where your country stands. The template letters section gives you tools to contact your elected representative or GP. You do not need to be an expert to advocate effectively. You need to know the facts and be willing to use them.